International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
about
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeImaging of multiple myeloma: Current conceptsMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementOvercoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysisTrends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.Myeloma today: Disease definitions and treatment advances.Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trialMultiple myeloma: 2012 update on diagnosis, risk-stratification, and management.Successful mobilization, intra-apheresis recruitment, and harvest of hematopoietic progenitor cells by addition of plerixafor and subsequent large-volume leukapheresis.Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myelomaHematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.Treatment of multiple myeloma: a comprehensive review.Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.How best to use new therapies in multiple myeloma.Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs.The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.Mobilization of hematopoietic stem cells into the peripheral blood.Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: a matter of undetermined significance.The evolving role of plerixafor in hematopoietic progenitor cell mobilization.Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.Controversies in multiple myeloma: to transplant or not?Novel agents and new therapeutic approaches for treatment of multiple myeloma.Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean mulNovel Induction Regimens in Multiple Myeloma.Hematopoietic stem cell mobilization: current status and future perspective.Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.Transplantation for Multiple Myeloma.Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.Multiple myeloma: an update.Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity.Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF.
P2860
Q26782868-3CA20BE3-98D9-420E-BCCA-11D3325BDD0CQ26864616-3C004C61-A197-4481-97C3-B03A0A51700BQ26998884-7F45567B-BDD9-4B06-AE5A-ACBFA79D63F9Q33405532-8C77FC17-B250-407C-9C87-1C5F53CACCB5Q33411277-388A58DF-63FA-4730-A72C-91860708FE68Q33692555-C102EDC3-602E-4290-87E3-CB02D6DA1CF2Q34253548-1C5E2269-9CD8-4EAB-AD24-11D8542892F9Q35172500-9150386F-E787-4142-ABF0-A79990D55A29Q35410550-02B576B5-5473-41AF-B770-10BF3097E184Q36470699-32E81A0D-AA99-4808-9D6F-8D239DE9052AQ36579055-4B2CDD01-31BC-46C7-8EED-CC9993F4AAD6Q36777233-C0D50493-814C-45A9-94CF-0EA8E9AA65AFQ37180930-865F4B0F-EB6C-4CF5-A39A-380293E44E7EQ37313790-222F24F4-64FC-44DE-9EED-E69A16FE4252Q37429206-2B42B9AF-C465-4F9F-958C-8DD285AF009AQ37515416-274501CE-5494-4FE0-A902-B4459FED8B47Q37542173-AC2F94D9-0E4D-4598-84AF-C790C0F2ACF0Q37623809-365A310F-54E4-4BA2-BF01-48A59345C0D4Q37723000-6EBA2064-3771-4AE3-A0D0-C1FF50C41AE0Q37785509-D8F6D58D-7868-4618-90C1-711ED5609116Q37800884-9A458E86-5864-48AF-9FEF-DF7AD566ABADQ37810088-925F1BC4-2D78-448E-8E06-1453C80EC420Q37827058-B463A210-D667-4A7F-AC97-1B7D6620E601Q37842346-B30A8606-F01E-4C9B-B367-E21DB0CF52F2Q37921284-E7A5AD39-13C1-40FB-9CD7-68AEFF280F4CQ37967069-46742FD7-8135-4884-931E-E132B6C0318CQ38077807-8751935B-C0EA-46B9-A84E-8FD01DC8B8A2Q38160461-9169C3A8-9FBA-47B8-91EB-4C3EE8B242C1Q38242006-8C0C174B-5713-4F9C-A55F-1212DEB1E7D1Q38261677-C50B7A5D-3ECA-446D-B7BC-A58F380C6359Q38418369-163CC195-8AE5-408D-A129-CB9DAF62C82DQ38567017-C530E64E-B7F5-438E-868F-41D2A1BE55B3Q38658893-3D842738-50A6-460C-A1F4-238BCFE6DD18Q38859426-F08E6EF1-5493-46B3-A984-031EF440E2DBQ38970603-327E20D5-3245-4B8B-BFF8-E9473127E864Q39066209-9813E48D-9CC6-4715-8565-BC7B85184546Q39471739-B1CDA9CF-BBC8-407C-AF52-9B1ABDB29132Q40543905-E46430CD-828E-4A25-A2B4-1FF62DA63B5CQ40621650-7B1A74CC-8872-43A7-B22C-8F4BFD1A2667Q41274044-98E80EEE-396B-4BA8-9BE4-F0F5BCD61586
P2860
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
International myeloma working ...... role of plerixafor (AMD 3100).
@en
International myeloma working group
@nl
type
label
International myeloma working ...... role of plerixafor (AMD 3100).
@en
International myeloma working group
@nl
prefLabel
International myeloma working ...... role of plerixafor (AMD 3100).
@en
International myeloma working group
@nl
P2093
P2860
P50
P356
P1433
P1476
International myeloma working ...... role of plerixafor (AMD 3100).
@en
P2093
B Barlogie
B G M Durie
E A Stadtmauer
I Turesson
P2860
P2888
P304
P356
10.1038/LEU.2009.127
P577
2009-06-25T00:00:00Z
P5875
P6179
1038640629